Other programs funded through Tackle Kids Cancer include:
2-Hydroxyoleic Acid Study to be launched in 2018. This new fatty acid drug has completed adult phase I testing in Europe with a positive response in advanced glioblastoma patients. When open, the trial will be open to patients with advanced brains and solid tumors, and will be a two-center study in cooperation with Dana-Farber Cancer Institute.
The Children’s Cancer Institute is New Jersey’s only pediatric bone marrow transplant center. The Transplant Clinical Trials Program focuses on improving cure rates as well as minimizing the short- and long-term side effects for children going through a bone marrow transplant.
Cure and Beyond Program is the most comprehensive survivorship program in New Jersey, and focuses on long-term health, emotional and social issues specific to pediatric cancer survivors.